Summary
In a significant market movement during October 2014, Cambridge Epigenetix was the subject of a vc funding. The transaction achieved a gross valuation of £3,401,494. Leading the round was New Science Ventures, Cambridge Enterprise, Syncona Partners.
This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.
Lead Investor / Acquirer
New Science Ventures
Lead Investor / Acquirer
Cambridge Enterprise
Lead Investor / Acquirer
Syncona Partners
Advising Broker
Undisclosed Firm
Related Deals in Healthcare & Biotech
Series A prioritisedOriginal Source
This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.
View on Tech.eu Funding ExplorerFunding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.
AI Insight Lenses
ProAI-generated analysis from four professional perspectives. Powered by PE Deals.
Sign in to unlock AI Lenses
Sign in